This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

AACR-NCI-EORTC Boston, MA, USA 26-30 October 2019

A Phase Ia/Ib, dose-escalation/expansion study of BI 907828, an MDM2-p53 antagonist, in combination with BI 754091, an anti-PD-1 antibody, and BI 754111, an anti-LAG-3 antibody, in patients with advanced solid tumors

Anthony Tolcher, Navid Hafez, Noboru Yamamoto, Jaehong Park, Rolf Grempler, Anthony Lucarelli, Markus P Vallaster, Hao Li, David Hyman

aacr_nci_eortc_mdm2_final

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

 

A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors

Curtis Chong, Todd Michael Bauer, Scott Andrew Laurie, Manish R. Patel, Noboru Yamamoto, Teffany Davenport, Junxian Geng, Neil Gibson, Markus P. Vallaster, Patricia LoRusso

asco_bi_907828_mdm2-p53_inhibitor_poster

RELATED INFORMATION

MDM2-p53 antagonist (BI 907828) + LAG-3 inhibitor (BI 754111) + PD-1 inhibitor (BI 754091)

MDM2-p53 antagonist (BI 907828) + LAG-3 inhibitor (BI 754111) + PD-1 inhibitor (BI 754091)

MDM2-p53 antagonist

Find out more about BI’s investigational MDM2-p53 antagonist, which is currently in clinical trials for the treatment of solid tumours

LAG-3 inhibitor (BI 754111) + PD-1 inhibitor (BI 754091)

LAG-3 inhibitor (BI 754111) + PD-1 inhibitor (BI 754091)
Back to top

FOR HEALTHCARE PROFESSIONALS ONLY

links_to_3rd_party.jpg